Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Front Immunol. 2021 Jul 5;12:647805. doi: 10.3389/fimmu.2021.647805. eCollection 2021.
Insight into inflammation patterns is needed to understand the pathophysiology of HIV and related cardiovascular disease (CVD). We assessed patterns of inflammation related to HIV infection and CVD risk assessed with carotid intima media thickness (CIMT).
A cross-sectional study was performed in Johannesburg, South Africa, including participants with HIV who were virally suppressed on anti-retroviral therapy (ART) as well as HIV-negative participants who were family members or friends to the HIV-positive participants. Information was collected on CVD risk factors and CIMT. Inflammation was measured with the Olink panel 'inflammation', allowing to simultaneously assess 92 inflammation markers. Differences in inflammation patterns between HIV-positive and HIV-negative participants were explored using a principal component analysis (PCA) and ANCOVA. The impact of differentiating immune markers, as identified by ANCOVA, on CIMT was assessed using linear regression while adjusting for classic CVD risk factors.
In total, 185 HIV-positive and 104 HIV negative participants, 63% females, median age 40.7 years (IQR 35.4 - 47.7) were included. HIV-positive individuals were older (+6 years, p <0.01) and had a higher CIMT (p <0.01). No clear patterns of inflammation were identified by use of PCA. Following ANCOVA, nine immune markers differed significantly between HIV-positive and HIV-negative participants, including PDL1. PDL1 was independently associated with CIMT, but upon stratification this effect remained for HIV-negative individuals only.
HIV positive patients on stable ART and HIV negative controls had similar immune activation patterns. CVD risk in HIV-positive participants was mediated by inflammation markers included in this study.
为了了解 HIV 和相关心血管疾病(CVD)的病理生理学,我们需要深入了解炎症模式。我们评估了与 HIV 感染相关的炎症模式以及通过颈动脉内膜中层厚度(CIMT)评估的 CVD 风险。
这项横断面研究在南非约翰内斯堡进行,包括接受抗逆转录病毒治疗(ART)且病毒得到抑制的 HIV 感染者以及作为 HIV 阳性参与者的家属或朋友的 HIV 阴性参与者。收集了 CVD 危险因素和 CIMT 信息。使用 Olink 面板“炎症”测量炎症,允许同时评估 92 种炎症标志物。使用主成分分析(PCA)和协方差分析(ANCOVA)探索 HIV 阳性和 HIV 阴性参与者之间的炎症模式差异。使用线性回归评估通过 ANCOVA 确定的区分免疫标志物对 CIMT 的影响,同时调整经典 CVD 危险因素。
共纳入 185 名 HIV 阳性和 104 名 HIV 阴性参与者,女性占 63%,中位年龄为 40.7 岁(IQR 35.4-47.7)。HIV 阳性个体年龄较大(+6 岁,p<0.01)且 CIMT 较高(p<0.01)。使用 PCA 未确定明确的炎症模式。经过 ANCOVA,9 种免疫标志物在 HIV 阳性和 HIV 阴性参与者之间存在显著差异,包括 PDL1。PDL1 与 CIMT 独立相关,但分层后仅对 HIV 阴性个体有此影响。
接受稳定 ART 治疗的 HIV 阳性患者和 HIV 阴性对照者具有相似的免疫激活模式。该研究中包含的炎症标志物介导了 HIV 阳性参与者的 CVD 风险。